Showing results (201-210 of 315) with videos related to

Sort By:
Pageof 32
Anti-Cancer Drugs|February 1, 1991
In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugsD S Alberts, R T Dorr, T P Wunz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinomaP J Stiff, R S McKenzie, D S Alberts, et al.
Genes, Chromosomes & Cancer|August 1, 1994
Simple numeric abnormalities as primary karyotype changes in ovarian carcinomaF H Thompson, Y Liu, J Emerson, et al.
Lancet (London, England)|August 16, 1980
In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapyD S Alberts, S E Samon, H S Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cellsD S Alberts, L A Speicher, M Krutzsch, et al.
Journal of Medicinal Chemistry|August 1, 1987
New antitumor agents containing the anthracene nucleusT P Wunz, R T Dorr, D S Alberts, et al.
Cancer Treatment Reports|June 1, 1982
Activity of isotretinoin against squamous cell cancers and preneoplastic lesionsF L Meyskens, E Gilmartin, D S Alberts, et al.
International Journal of Immunopathology and Pharmacology|June 11, 2011
Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysisR Mazzucchelli, M Scarpelli, A Lopez-Beltran, et al.
Cancer Research|October 15, 1988
Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administrationD S Alberts, E A Surwit, Y M Peng, et al.
Gynecologic Oncology|June 1, 1987
Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group StudyE A Surwit, D S Alberts, R V O'Toole, et al.
Pageof 32